Kelsey L Corrigan1, Stephen Kry2, Rebecca M Howell3, Ramez Kouzy4, Joseph Abi Jaoude5, Roshal R Patel6, Anuja Jhingran7, Cullen Taniguchi8, Albert C Koong9, Mary Fran McAleer10, Paige Nitsch11, Claus Rödel12, Emmanouil Fokas13, Bruce D Minsky14, Prajnan Das15, C David Fuller16, Ethan B Ludmir17. 1. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: KLCorrigan@mdanderson.org. 2. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: SFKry@mdanderson.org. 3. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: RHowell@mdanderson.org. 4. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: RKouzy@mdanderson.org. 5. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: JBabi@mdanderson.org. 6. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: roshal.r.patel@kp.org. 7. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: AJhingra@mdanderson.org. 8. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: CTaniguchi@mdanderson.org. 9. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: AKoong@mdanderson.org. 10. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: MFMcalee@mdanderson.org. 11. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: PLNitsch@mdanderson.org. 12. University of Frankfurt, Frankfurt, Germany; German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany. Electronic address: ClausMichael.Roedel@kgu.de. 13. University of Frankfurt, Frankfurt, Germany; German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany. Electronic address: Emmanouil.Fokas@kgu.de. 14. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: BMinsky@mdanderson.org. 15. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: PrajDas@mdanderson.org. 16. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: CDFuller@mdanderson.org. 17. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: EBLudmir@mdanderson.org.
Abstract
PURPOSE: Quality assurance (QA) practices improve the quality level of oncology trials by ensuring that the protocol is followed and the results are valid and reproducible. This study investigated the utilization of QA among randomized controlled trials that involve radiotherapy (RT). METHODS AND MATERIALS: We searched ClinicalTrials.gov in February 2020 for all phase III oncology randomized clinical trials (RCTs). These trials were screened for RT-specific RCTs that had published primary trial results. Information regarding QA in each trial was collected from the study publications and trial protocol if available. Two individuals independently performed trial screening and data collection. Pearson's Chi-square tests analyses were used to assess factors that were associated with QA inclusion in RT trials. RESULTS: Forty-two RCTs with RT as the primary intervention or as a mandatory component of the protocol were analyzed; the earliest was started in 1994 and one trial was still active though not recruiting. Twenty-nine (69%) trials mandated RT quality assurance (RTQA) practices as part of the trial protocol, with 19 (45%) trials requiring institutional credentialing. Twenty-one (50%) trials published protocol deviation outcomes. Clinical trials involving advanced radiation techniques (IMRT, VMAT, SRS, SBRT) did not include more RTQA than trials without these advanced techniques (73% vs. 65%, p = 0.55). Trials that reported protocol deviation outcomes were associated with mandating RTQA in their protocols as compared to trials that did not report these outcomes (100% vs. 38%, p < 0.001). CONCLUSIONS: There is a lack of RTQA utilization and transparency in RT clinical trials. It is imperative for RT trials to include increased QA for safe, consistent, and high-quality RT planning and delivery.
PURPOSE: Quality assurance (QA) practices improve the quality level of oncology trials by ensuring that the protocol is followed and the results are valid and reproducible. This study investigated the utilization of QA among randomized controlled trials that involve radiotherapy (RT). METHODS AND MATERIALS: We searched ClinicalTrials.gov in February 2020 for all phase III oncology randomized clinical trials (RCTs). These trials were screened for RT-specific RCTs that had published primary trial results. Information regarding QA in each trial was collected from the study publications and trial protocol if available. Two individuals independently performed trial screening and data collection. Pearson's Chi-square tests analyses were used to assess factors that were associated with QA inclusion in RT trials. RESULTS: Forty-two RCTs with RT as the primary intervention or as a mandatory component of the protocol were analyzed; the earliest was started in 1994 and one trial was still active though not recruiting. Twenty-nine (69%) trials mandated RT quality assurance (RTQA) practices as part of the trial protocol, with 19 (45%) trials requiring institutional credentialing. Twenty-one (50%) trials published protocol deviation outcomes. Clinical trials involving advanced radiation techniques (IMRT, VMAT, SRS, SBRT) did not include more RTQA than trials without these advanced techniques (73% vs. 65%, p = 0.55). Trials that reported protocol deviation outcomes were associated with mandating RTQA in their protocols as compared to trials that did not report these outcomes (100% vs. 38%, p < 0.001). CONCLUSIONS: There is a lack of RTQA utilization and transparency in RT clinical trials. It is imperative for RT trials to include increased QA for safe, consistent, and high-quality RT planning and delivery.
Authors: Ross A Abrams; Kathryn A Winter; William F Regine; Howard Safran; John P Hoffman; Robert Lustig; Andre A Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-01 Impact factor: 7.038
Authors: Thomas Bortfeld; Alberto Torresin; Claudio Fiorino; Pedro Andreo; Giovanna Gagliardi; Robert Jeraj; Ludvig P Muren; Marta Paiusco; David Thwaites; Tommy Knöös Journal: Radiother Oncol Date: 2015-02-26 Impact factor: 6.280
Authors: Mallory E Carson; Andrea Molineu; Paige A Taylor; David S Followill; Francesco C Stingo; Stephen F Kry Journal: Med Phys Date: 2016-12 Impact factor: 4.071
Authors: Christos Melidis; Walter R Bosch; Joanna Izewska; Elena Fidarova; Eduardo Zubizarreta; Satoshi Ishikura; David Followill; James Galvin; Ying Xiao; Martin A Ebert; Tomas Kron; Catharine H Clark; Elizabeth A Miles; Edwin G A Aird; Damien C Weber; Kenneth Ulin; Dirk Verellen; Coen W Hurkmans Journal: Radiother Oncol Date: 2014-05-08 Impact factor: 6.280
Authors: Jean M Moran; Andrea Molineu; Jon J Kruse; Mark Oldham; Robert Jeraj; James M Galvin; Jatinder R Palta; Arthur J Olch Journal: J Appl Clin Med Phys Date: 2018-06-29 Impact factor: 2.102